Avril Dieser
Fortuna: 10 700 $ al 31/05/2026
Fortuna: 10 700 $ al 31/05/2026
Avril McKean Dieser is an Independent Non-Executive Director at OS Therapies, Inc. since 2024.
Ms. Dieser is Vice President & Head-Legal Patient Evidence at UCB, Inc. since 2016.
Ms. Dieser was a Member at AbbVie, Inc. from 2013 to 2016.
Ms. Dieser completed graduate degrees at the University of Maryland and Columbus School of Law, and an undergraduate degree at Duquesne University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 22/01/2026 | 5.000 ( 0,01 % ) | 10 700 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| OS THERAPIES INCORPORATED | Director/Miembro de la Junta | 28/10/2024 |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Corporate Officer/Principal | 01/08/2016 |
| Empresas | Cargo | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/07/2016 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OS Therapies, Inc.
OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.